Overview of The Villages of Windcrest The Villages of Windcrest operates an 86-bed nursing home at 702 W Windcrest St in Fredericksburg’s Gillespie County, administered by Mr. Kraig A Turpen under Acron Windcrest Village LLC.
The two-story facility has provided nursing home, assisted living, and memory care (including 24 dedicated Alzheimer’s units) for seven years, serving a mixed payer population: 35% Medicare residents (typically short-term rehab), 22% Medicaid, and 43% private pay. Current occupancy is 59.6%, lower than the Texas average of 63.5%, with average resident stays extending to 202 days.
The facility holds a 1-star overall CMS rating, 66.8% below Texas average. This reflects a 1-star Health Inspection rating (65.4% below state average) and a 1-star Staffing rating (58.3% below state average).
Seven state inspections since 2022 resulted in 45 health citations; placing the facility at the 257th precentile among 292 Texas nursing homes, among the worst-performing in the state.
Citations average 6.43 per inspection, the second-worst rate statewide. Five deficiencies reached critical severity, 150% worse than the state average. The primary problems cluster in documentation and quality of life (8 deficiencies), resident rights (6), abuse and neglect safeguards (6), pharmacy services (5), and infection control (3).
The facility has incurred $94,000 in federal penalties across three assessments since 2024, culminating in a $49,000 civil money penalty in January 2025 and a $2,250 administrative penalty in October 2024 for failures in abuse and neglect protection.
Resident outcome measures reveal safety gaps. Falls with major injury occurred in 7.1% of long-stay residents; more than double the state average of 3.2%. Walking ability declined in 23.4% of residents, 44% worse than the state norm.
Staffing ratios exceed state average (1.82:1 vs. 1.48:1), though 47% of staff are contractors. Payroll represents 31.4% of revenue, significantly below the sustainable 51–63% range typical of well-run facilities.
The facility’s regulatory and clinical trajectory presents unresolved safety concerns and elevated risk across standard quality metrics.